KECORT Study: An International e-Delphi Study on the Treatment of KEloids Using Intralesional CORTicosteroids in Clinical Practice.
Journal
American journal of clinical dermatology
ISSN: 1179-1888
Titre abrégé: Am J Clin Dermatol
Pays: New Zealand
ID NLM: 100895290
Informations de publication
Date de publication:
19 Sep 2024
19 Sep 2024
Historique:
accepted:
25
08
2024
medline:
20
9
2024
pubmed:
20
9
2024
entrez:
19
9
2024
Statut:
aheadofprint
Résumé
Intralesional corticosteroid administration (ICA) is a first-line keloid treatment. However, it faces significant variability in current clinical and scientific practice, which hinders comparability of treatment results. The aim of the study was to reach consensus on different aspects of ICA using hypodermic needles in keloids among an international group of dermatologists and plastic surgeons specialized in keloid treatment to provide consensus-based clinical treatment recommendations for all physicians treating keloids. The keloid expert panel of 12 dermatologists and 11 plastic surgeons rated 30 statements. Two online e-Delphi rounds were held, both with a response rate of 100%. Fifteen (65%) keloid experts participated in the final consensus meetings. Consensus was defined as ≥ 75% of the participants choosing agree or strongly agree on a 7-point Likert scale. Consensus was reached on treatment goals, indication for ICA, triamcinolone acetonide (TAC) 40 mg/mL as the preferred corticosteroid administered at a maximum of 80 mg per month and at intervals of 4 weeks, minimizing pain during ICA, the use of 1 mL syringes and 25 or 27 Gauge needles, blanching as endpoint of successful infiltration, caution of not injecting subcutaneously, and the option of making multiple passes in very firm keloids prior to infiltration. Consensus could not be reached on TAC dosing, methods of prior local anesthesia, and location of injection. This e-Delphi study provides important clinical treatment recommendations on essential aspects of ICA in keloids. By implementing these recommendations, uniformity of ICA in keloid treatment will increase and better treatment results may be achieved.
Sections du résumé
BACKGROUND
BACKGROUND
Intralesional corticosteroid administration (ICA) is a first-line keloid treatment. However, it faces significant variability in current clinical and scientific practice, which hinders comparability of treatment results.
OBJECTIVES
OBJECTIVE
The aim of the study was to reach consensus on different aspects of ICA using hypodermic needles in keloids among an international group of dermatologists and plastic surgeons specialized in keloid treatment to provide consensus-based clinical treatment recommendations for all physicians treating keloids.
METHODS
METHODS
The keloid expert panel of 12 dermatologists and 11 plastic surgeons rated 30 statements. Two online e-Delphi rounds were held, both with a response rate of 100%. Fifteen (65%) keloid experts participated in the final consensus meetings. Consensus was defined as ≥ 75% of the participants choosing agree or strongly agree on a 7-point Likert scale.
RESULTS
RESULTS
Consensus was reached on treatment goals, indication for ICA, triamcinolone acetonide (TAC) 40 mg/mL as the preferred corticosteroid administered at a maximum of 80 mg per month and at intervals of 4 weeks, minimizing pain during ICA, the use of 1 mL syringes and 25 or 27 Gauge needles, blanching as endpoint of successful infiltration, caution of not injecting subcutaneously, and the option of making multiple passes in very firm keloids prior to infiltration. Consensus could not be reached on TAC dosing, methods of prior local anesthesia, and location of injection.
CONCLUSIONS
CONCLUSIONS
This e-Delphi study provides important clinical treatment recommendations on essential aspects of ICA in keloids. By implementing these recommendations, uniformity of ICA in keloid treatment will increase and better treatment results may be achieved.
Identifiants
pubmed: 39298112
doi: 10.1007/s40257-024-00888-7
pii: 10.1007/s40257-024-00888-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Mustoe TA, Cooter RD, Gold MH, Hobbs FD, Ramelet AA, Shakespeare PG, et al. International clinical recommendations on scar management. Plast Reconstr Surg. 2002;110:560–71.
pubmed: 12142678
doi: 10.1097/00006534-200208000-00031
Ogawa R, Akita S, Akaishi S, Aramaki-Hattori N, Dohi T, Hayashi T, et al. Diagnosis and treatment of keloids and hypertrophic scars-Japan scar workshop consensus document 2018. Burns Trauma. 2019;7:39.
pubmed: 31890718
pmcid: 6933735
doi: 10.1186/s41038-019-0175-y
Wang CJ, Ko JY, Chou WY, Cheng JH, Kuo YR. Extracorporeal shockwave therapy for treatment of keloid scars. Wound Repair Regen. 2018;26:69–76.
pubmed: 29330940
doi: 10.1111/wrr.12610
Kaushal V, Kumar S, Brar BK, Singh A. Comparative evaluation of therapeutic efficacy and safety of intralesional triamcinolone acetonide injection vs intralesional radiofrequency with intralesional triamcinolone acetonide in treatment of keloids. Dermatol Ther. 2020;33: e13919.
pubmed: 32594600
doi: 10.1111/dth.13919
Yin Q, Louter JMI, Niessen FB, Gibbs S, Tasdemir-Kilic G, Lapid O, et al. Intralesional corticosteroid administration in the treatment of keloids: a scoping review on injection methods. Dermatology. 2023.
Yin Q, Niessen FB, Gibbs S, Lapid O, Louter JMI, van Zuijlen PPM, Wolkerstorfer A. Intralesional corticosteroid administration in the treatment of keloids: a survey among Dutch dermatologists and plastic surgeons. J Dermatolog Treat. 2023;34:2159308.
pubmed: 36594683
doi: 10.1080/09546634.2022.2159308
Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, Wales PW. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol. 2014;67:401–9.
pubmed: 24581294
doi: 10.1016/j.jclinepi.2013.12.002
Wang X, Wu X, Liu K, Xia L, Lin X, Liu W, Gao Z. Topical cryoanesthesia for the relief of pain caused by steroid injections used to treat hypertrophic scars and keloids. Medicine (Baltimore). 2017;96: e8353.
pubmed: 29069016
doi: 10.1097/MD.0000000000008353
Jongkajornpong N WK. The efficacy of skin cooling for pain relief during intralesional steroid injection for keloid treatment: a randomized cross-over study. J Med Assoc Thailand. 2021:1752–7.
Limandjaja GC, van den Broek LJ, Waaijman T, van Veen HA, Everts V, Monstrey S, et al. Increased epidermal thickness and abnormal epidermal differentiation in keloid scars. Br J Dermatol. 2017;176:116–26.
pubmed: 27377288
doi: 10.1111/bjd.14844
Jiao H, Zhang T, Fan J, Xiao R. The superficial dermis may initiate keloid formation: histological analysis of the keloid dermis at different depths. Front Physiol. 2017;8:885.
pubmed: 29163221
pmcid: 5682018
doi: 10.3389/fphys.2017.00885
Syed F, Ahmadi E, Iqbal SA, Singh S, McGrouther DA, Bayat A. Fibroblasts from the growing margin of keloid scars produce higher levels of collagen I and III compared with intralesional and extralesional sites: clinical implications for lesional site-directed therapy. Br J Dermatol. 2011;164:83–96.
pubmed: 20849516
doi: 10.1111/j.1365-2133.2010.10048.x
Simpson RC, Kirtschig G, Selk A, von Seitzberg S, Vittrup G, Bissonnette I, et al. Core outcome domains for lichen sclerosus: a CORALS initiative consensus statement. Br J Dermatol. 2023;188:628–35.
pubmed: 36702803
doi: 10.1093/bjd/ljac145
Young AM, Chung H, Chaplain A, Lowe JR, Wallace SJ. Development of a minimum dataset for subacute rehabilitation: a three-round e-Delphi consensus study. BMJ Open. 2022;12: e058725.
pubmed: 35338067
pmcid: 8961134
doi: 10.1136/bmjopen-2021-058725
Mirmovich O, Gil T, Goldin I, Lavi I, Mettanes I, Har-Shai Y. Pain evaluation and control during and following the treatment of hypertrophic scars and keloids by contact and intralesional cryosurgery—a preliminary study. J Eur Acad Dermatol Venereol. 2012;26:440–7.
pubmed: 21557777
doi: 10.1111/j.1468-3083.2011.04092.x
Searle T, Ali FR, Al-Niaimi F. The role of pharmacogenetics in keloid scar treatment: a literature review. Scars Burn Heal. 2020;6:2059513120941704.
pubmed: 32922964
pmcid: 7446553
Furtado F, Hochman B, Ferrara SF, Dini GM, Nunes JM, Juliano Y, Ferreira LM. What factors affect the quality of life of patients with keloids? Rev Assoc Med Bras. 1992;2009(55):700–4.
Bijlard E, Kouwenberg CA, Timman R, Hovius SE, Busschbach JJ, Mureau MA. Burden of keloid disease: a cross-sectional health-related quality of life assessment. Acta Derm Venereol. 2017;97:225–9.
pubmed: 27378582
doi: 10.2340/00015555-2498
Bari H. A prolonged release parenteral drug delivery system—an overview. Int J Pharm Sci Rev Res. 2010;3:1–11.
Benzon HT, Chew TL, McCarthy RJ, Benzon HA, Walega DR. Comparison of the particle sizes of different steroids and the effect of dilution: a review of the relative neurotoxicities of the steroids. Anesthesiology. 2007;106:331–8.
pubmed: 17264728
doi: 10.1097/00000542-200702000-00022
Firooz A, Tehranchi-Nia Z, Ahmed AR. Benefits and risks of intralesional corticosteroid injection in the treatment of dermatological diseases. Clin Exp Dermatol. 1995;20:363–70.
pubmed: 8593711
doi: 10.1111/j.1365-2230.1995.tb01351.x
MacMahon PJ, Shelly MJ, Scholz D, Eustace SJ, Kavanagh EC. Injectable corticosteroid preparations: an embolic risk assessment by static and dynamic microscopic analysis. AJNR Am J Neuroradiol. 2011;32:1830–5.
pubmed: 21940803
pmcid: 7965993
doi: 10.3174/ajnr.A2656
Tiso RL, Cutler T, Catania JA, Whalen K. Adverse central nervous system sequelae after selective transforaminal block: the role of corticosteroids. Spine J. 2004;4:468–74.
pubmed: 15246308
doi: 10.1016/j.spinee.2003.10.007
Kahn CB, Hollander JL, Schumacher HR. Corticosteroid crystals in synovial fluid. JAMA. 1970;211:807–9.
pubmed: 4320615
doi: 10.1001/jama.1970.03170050041009
Woliansky J, Phyland D, Paddle P. Systemic safety of serial intralesional steroid injection for subglottic stenosis. Laryngoscope. 2019;129:1634–9.
pubmed: 30582619
doi: 10.1002/lary.27673
Cevc G, Blume G. Biological activity and characteristics of triamcinolone-acetonide formulated with the self-regulating drug carriers. Transfersomes Biochim Biophys Acta. 2003;1614:156–64.
pubmed: 12896808
doi: 10.1016/S0005-2736(03)00172-X
Spitzer MS, Kaczmarek RT, Yoeruek E, Petermeier K, Wong D, Heimann H, et al. The distribution, release kinetics, and biocompatibility of triamcinolone injected and dispersed in silicone oil. Invest Ophthalmol Vis Sci. 2009;50:2337–43.
pubmed: 19098319
doi: 10.1167/iovs.08-2471
Fernandes-Cunha GM, Saliba JB, Siqueira RC, Jorge R, Silva-Cunha A. Determination of triamcinolone acetonide in silicone oil and aqueous humor of vitrectomized rabbits’ eyes: application for a pharmacokinetic study with intravitreal triamcinolone acetonide injections (Kenalog
pubmed: 24252721
doi: 10.1016/j.jpba.2013.10.025
Li J, Lee K, Chang D, Boominathan P, Banack T. A breast cancer survivor’s self-controlled case report: methylprednisolone acetate provided a week longer analgesia than dexamethasone sodium phosphate via thoracic paravertebral blockade. Cureus. 2019;11: e6085.
pubmed: 31853436
pmcid: 6894892
Jobe AH, Milad MA, Peppard T, Jusko WJ. Pharmacokinetics and pharmacodynamics of intramuscular and oral betamethasone and dexamethasone in reproductive age women in India. Clin Transl Sci. 2020;13:391–9.
pubmed: 31808984
doi: 10.1111/cts.12724
SmPC KenaCort. https://www.geneesmiddeleninformatiebank.nl/smpc/h05341_smpc.pdf .
Jarratt MT, Spark RF, Arndt KA. The effects of intradermal steroids on the pituitary-adrenal axis and the skin. J Invest Dermatol. 1974;62:463–6.
pubmed: 4820688
doi: 10.1111/1523-1747.ep12701707
Zaynoun ST, Salti IS. The effect of intracutaneous glucocorticoids on plasma cortisol levels. Br J Dermatol. 1973;88:151–6.
pubmed: 4735911
doi: 10.1111/j.1365-2133.1973.tb07520.x
Mcgugan AD, Shuster S, Bottoms E. Adrenal suppression from intradermal triamcinolone. J Invest Dermatol. 1963;40:271–2.
Samtani MN, Lohle M, Grant A, Nathanielsz PW, Jusko WJ. Betamethasone pharmacokinetics after two prodrug formulations in sheep: implications for antenatal corticosteroid use. Drug Metab Dispos. 2005;33:1124–30.
pubmed: 15860658
doi: 10.1124/dmd.105.004309
Pfizer medical information: provided upon request. 2022.
Potter RA. Intralesional triamcinolone and adrenal suppression in acne vulgaris. J Invest Dermatol. 1971;57:364–70.
pubmed: 4256835
doi: 10.1111/1523-1747.ep12292717
Fredman R, Tenenhaus M. Cushing’s syndrome after intralesional triamcinolone acetonide: a systematic review of the literature and multinational survey. Burns. 2013;39:549–57.
pubmed: 23092701
doi: 10.1016/j.burns.2012.09.020
Aluko-Olokun B, Olaitan AA, Ladeinde AL, Aluko-Olokun OA, Alade MO, Ibukun-Obaro O, Adenaike FS. Determination of the optimal frequency of injection of triamcinolone: monitoring change in volume of keloid lesions following injection of 40 mg of triamcinolone. Eur J Plast Surg. 2016;39:119–24.
doi: 10.1007/s00238-015-1139-5
Stern SF, Shuman A. The effect of locally administered corticosteroids (soluble and insoluble) on the healing times of surgically induced wounds in guinea pigs. J Am Podiatry Assoc. 1973;63:374–82.
pubmed: 4717107
doi: 10.7547/87507315-63-8-374
Srivasta. Comparison of efficacy of intralesional triamcinolone acetonide at 2-, 4-, and 6-week intervals in hypertrophic scars and keloids. Indian J Burns. 2021;29.
Muneuchi G, Suzuki S, Onodera M, Ito O, Hata Y, Igawa HH. Long-term outcome of intralesional injection of triamcinolone acetonide for the treatment of keloid scars in Asian patients. Scand J Plast Reconstr Surg Hand Surg. 2006;40:111–6.
pubmed: 16537259
doi: 10.1080/02844310500430003
Salem A, Assaf M, Helmy A, Nofal A, Ibrahim S, Eldeeb F, Youssef C. Role of vascular endothelial growth factor in keloids: a clinicopathologic study. Int J Dermatol. 2009;48:1071–7.
pubmed: 19775400
doi: 10.1111/j.1365-4632.2009.04143.x
Uzair. Comparison of intralesional triamcinolone and intralesional verapamil in the treatment of keloids. Dermatol Online. 2015.
Nor NM, Ismail R, Jamil A, Shah SA, Imran FH. A randomized, single-blind trial of clobetasol propionate 0.05% cream under silicone dressing occlusion versus intra-lesional triamcinolone for treatment of keloid. Clin Drug Investig. 2017;37:295–301.
Srivastava S, Patil A, Prakash C, Kumari H. Comparison of intralesional triamcinolone acetonide, 5-fluorouracil, and their combination in treatment of keloids. World J Plast Surg. 2018;7:212–9.
pubmed: 30083505
pmcid: 6066718
Albalat W, Nabil S, Khattab F. Assessment of various intralesional injections in keloid: comparative analysis. J Dermatolog Treat. 2022;33:2051–6.
pubmed: 33849382
doi: 10.1080/09546634.2021.1914307
Okabe. Local injection of lidocaine around keloids and hypertrophic scars dramatically relieves pain following intralesional injection of triamcinolone acetonide. In: Papers of the 6th Japan scar workshop; Japan. 2012.
Azad S, Sacks L. Painless steroid injections for hypertrophic scars and keloids. Br J Plast Surg. 2002;55:534.
pubmed: 12479437
doi: 10.1054/bjps.2002.3913
Chuang GS, Rogers GS, Zeltser R. Poiseuille’s law and large-bore needles: insights into the delivery of corticosteroid injections in the treatment of keloids. J Am Acad Dermatol. 2008;59:167–8.
pubmed: 18571605
doi: 10.1016/j.jaad.2008.02.017
Jongkajornpong N, Wattanawong K. The efficacy of skin cooling for pain relief during intralesional steroid injection for keloid treatment: a randomized cross-over study. J Med Assoc Thai. 2021;104:1752–7.
doi: 10.35755/jmedassocthai.2021.11.13191
Nduka C, van Dam H, Davis K, Shibu M. Painless steroid injections for hypertrophic scars and keloids. Br J Plast Surg. 2003;56:842.
pubmed: 14615270
doi: 10.1016/j.bjps.2003.03.001
Al-Qarqaz F, Al-Aboosi M, Al-shiyab D, Al DZ. Using cold air for reducing needle-injection pain. Int J Dermatol. 2012;51:848–52.
pubmed: 22715833
doi: 10.1111/j.1365-4632.2011.05383.x
Usanakornkul A, Burusapat C. A topical anesthetic and lidocaine mixture for pain relief during keloid treatment: a double-blind, randomized controlled trial. Dermatol Surg. 2017;43:66–73.
pubmed: 28027198
doi: 10.1097/DSS.0000000000000932
Huang W, Vidimos A. Topical anesthetics in dermatology. J Am Acad Dermatol. 2000;43:286–98.
pubmed: 10906653
doi: 10.1067/mjd.2000.106506
Ono N. Pain-free intralesional injection of triamcinolone for the treatment of keloid. Scand J Plast Reconstr Surg Hand Surg. 1999;33:89–91.
pubmed: 10207970
doi: 10.1080/02844319950159677
Mandal A, Imran D. Painless steroid injections for hypertrophic scars and keloids. Br J Plast Surg. 2003;56:79.
pubmed: 12706172
doi: 10.1016/S0007-1226(03)00016-X
Vo A, Doumit M, Rockwell G. The biomechanics and optimization of the needle-syringe system for injecting triamcinolone acetonide into keloids. J Med Eng. 2016;2016:5162394.
pubmed: 27843936
pmcid: 5098087
doi: 10.1155/2016/5162394
Hietanen KE, Järvinen TA, Huhtala H, Tolonen TT, Kuokkanen HO, Kaartinen IS. Treatment of keloid scars with intralesional triamcinolone and 5-fluorouracil injections—a randomized controlled trial. J Plast Reconstr Aesthet Surg. 2019;72:4–11.
pubmed: 30448246
doi: 10.1016/j.bjps.2018.05.052